KTRA 外匯新聞

Biopharmaceutical company Kintara Therapeutics, Inc. (KTRA) and immune-oncology company TuHURA Biosciences, Inc. announced Wednesday that they have entered into a definitive agreement for an all-stock transaction forming a company with expertise and resources to advance a risk diversified late-stage oncology pipeline.